Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 28M |
| Gross Profit | -1M | -1M | -1M | -1M | 27M |
| Operating Income | -38M | -45M | -36M | -24M | -39M |
| EBITDA | -37M | -50M | -33M | -24M | -52M |
| Net Income | -40M | -52M | -35M | -28M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.75
-5.78% today
1Y Change
-40.38%
Window
Jun 27, 2025 → Jun 17, 2026
Coverage: 244 bars · Jun 27, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Elicio Therapeutics, Inc. (ELTX) is a Healthcare stock with a market cap of $200.00M and listed on NASDAQ. The stock last traded around $3.75 and down 40.4% across the available one-year price window (Jun 27, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +39.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +39.3%, free cash flow +0.5% with operating margin 0.0% and ROIC -201.0%. Stock Foundry combines ELTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ELTX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ELTX Max Drawdown
-81.41%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ELTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$28.3M
FY Net Income
-$26.4M
+6.4% YoY
Free Cash Flow
-$24.5M
-7.1% YoY
Revenue Growth
+0.0%
EPS Growth
+39.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 28M |
| Gross Profit | -1M | -1M | -1M | -1M | 27M |
| Operating Income | -38M | -45M | -36M | -24M | -39M |
| EBITDA | -37M | -50M | -33M | -24M | -52M |
| Net Income | -40M | -52M | -35M | -28M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 19M | 18M | 13M | 8M | 89M |
| Total Assets | 26M | 28M | 27M | 23M | 97M |
| Total Liabilities | 24M | 39M | 16M | 14M | 15M |
| Shareholder Equity | 2M | -11M | 11M | 9M | 82M |
| Total Debt | 15M | 26M | 7M | 7M | 5M |
| Net Debt | -4M | 8M | -6M | -316K | -84M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24M
-7.9% YoY
Capital Expenditures
525K
+19.7% YoY
Free Cash Flow
24M
-7.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-977.7%
Debt / Equity
3.12x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.